Use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) produces dramatic response and favorable prognosis in patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations, especially exon 19 deletion and exon 21 L858R point mutations [2]. Here, EGFR is linked to lung adenocarcinoma.